# A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants

> **NCT04927065** · PHASE2,PHASE3 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 5161 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** mRNA-1273.211
- **BIOLOGICAL:** mRNA-1273
- **BIOLOGICAL:** mRNA-1273.617.2
- **BIOLOGICAL:** mRNA-1273.213
- **BIOLOGICAL:** mRNA-1273.529
- **BIOLOGICAL:** mRNA-1273.214
- **BIOLOGICAL:** mRNA-1273.222
- **BIOLOGICAL:** mRNA-1273.815
- **BIOLOGICAL:** mRNA-1273.231

## Key facts

- **NCT ID:** NCT04927065
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-28
- **Primary completion:** 2023-11-17
- **Final completion:** 2023-11-17
- **Target enrollment:** 5161 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04927065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04927065, "A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04927065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*